A
Andrea E. Crompton
Researcher at Harvard University
Publications - 3
Citations - 253
Andrea E. Crompton is an academic researcher from Harvard University. The author has contributed to research in topics: Warfarin & Atrial fibrillation. The author has an hindex of 3, co-authored 3 publications receiving 193 citations. Previous affiliations of Andrea E. Crompton include Brigham and Women's Hospital & Daiichi Sankyo.
Papers
More filters
Journal ArticleDOI
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Mark S. Link,Robert P. Giugliano,Christian T. Ruff,Benjamin M. Scirica,Heikke Huikuri,Ali Oto,Andrea E. Crompton,Sabina A. Murphy,Hans Lanz,Hans Lanz,Michele Mercuri,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +13 more
TL;DR: Patients with paroxysmal AF suffered fewer thromboembolic events and deaths compared with those with persistent and permanent AF, and the efficacy and safety profile of edoxaban as compared with warfarin was consistent across the 3 patterns of AF.
Journal ArticleDOI
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Natalia S. Rost,Robert P. Giugliano,Christian T. Ruff,Sabina A. Murphy,Andrea E. Crompton,Andrew D. Norden,Scott Silverman,Aneesh B. Singhal,Jose C. Nicolau,Bhupathi SomaRaju,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +12 more
TL;DR: HDER is at least as effective and is safer than warfarin, regardless of the presence or the absence of previous IS or TIA, and annualized intracranial hemorrhage rates were lower with HDER than with warfar in this prespecified subgroup analysis.
Journal ArticleDOI
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Christian T. Ruff,Robert P. Giugliano,Eugene Braunwald,Michele Mercuri,Valentin Curt,Joshua Betcher,Laura T. Grip,Abby Cange,Andrea E. Crompton,Sabina A. Murphy,Naveen Deenadayalu,Elliott M. Antman +11 more
TL;DR: The ENGAGE AF-TIMI 48 transition plan protected patients from an excess of thrombotic and bleeding events and should be helpful in clinical practice when patients are transitioned between oral anticoagulants.